EODData

MEMBERSHIP REGISTER LOG IN

OTCBB, TLPPF: Telix Pharmaceutical Ltd

15 Oct 2025
LAST:

10.80

CHANGE:
 1.05		OPEN:
10.43		HIGH:
11.00		ASK:
0.00		VOLUME:
1.9K
CHG(%):
10.77		PREV:
9.75		LOW:
10.43		BID:
0.00		 

CHART

RECENT END OF DAY PRICES

DateOpenHighLowCloseVolume
15 Oct 2510.4311.0010.4310.801.9K
14 Oct 259.509.759.509.751.7K
10 Oct 2510.0010.0010.0010.00200
08 Oct 259.509.549.509.54400
07 Oct 259.519.519.519.511K
06 Oct 259.509.509.509.502K
03 Oct 259.959.959.509.903.2K
02 Oct 259.679.679.679.67400
01 Oct 259.3610.019.369.36300
30 Sep 259.1910.079.189.304.8K

COMPANY PROFILE

Name:Telix Pharmaceutical Ltd
About:Telix Pharmaceuticals Limited, a commercial-stage biopharmaceutical company, focuses on the development and commercialization of therapeutic and diagnostic radiopharmaceuticals. The company operates through three segments: Precision Medicine, Therapeutics, and Manufacturing Solutions. Its lead therapeutic product candidate is TLX591, a lutetium-labeled radio antibody-drug conjugate (rADC), which is in a Phase 3 clinical trial in patients with advanced prostate cancer. The company develops TLX250, an rADC for treating advanced metastatic kidney cancer; TLX101, a systemic therapy for the treatment of glioblastoma; TLX66, a product candidate for bone marrow conditioning for hematopoietic stem cell transplant conditioning; and Illuccix and Gozellix for the treatment of prostate cancer. The company is also developing TLX592, a prostate cancer therapy candidate for targeted alpha therapy based on its proprietary RADmAb-engineered antibody technology; TLX252 for the treatment of patients with advanced metastatic kidney cancer; TLX400, a bladder fibroblast activation protein for treating various tumors; TLX102, a large amino acid transporter-targeting small molecule-based alpha therapy candidate for the treatment of glioblastoma and multiple myeloma; TLX300 for treating soft tissue sarcoma; and TLX090, a bone-seeking agent for bone metastases and pain palliation. In addition, it is developing TLX250-CDx, a positron emission tomography (PET) diagnostic imaging agent for the characterization of renal masses as clear cell renal cell carcinoma; TLX101-CDx, a PET diagnostic agent to image cancerous lesions in the brain; and TLX66-CDx, a cluster of differentiation 66 imaging agent for osteomyelitis (bone infection). It operates in Australia, Belgium, Canada, the United Kingdom, the United States, and internationally. The company was founded in 2015 and is headquartered in North Melbourne, Australia.
Sector:Healthcare
Industry:Biotechnology
Address:55 Flemington Road, North Melbourne, VIC, Australia, 3051
Website:https://telixpharma.com
CIK:0002007191
FIGI:BBG00LJTBT58

API SERVICE  NEW

Have you tried our new API Service yet?

For more information, visit our API page.

You can get your ApiKey over HERE.

If you're ready to get going, then jump over to:
https://api.eoddata.com

SYMBOL HISTORY

   Add to Watchlist

DOWNLOAD DATA

Download stock quote history quickly and easily in a variety of formats to suit your needs.

  Download

FUNDAMENTALS

Trailing P/E:475.00 
Forward P/E:57.47 
Price to Book:7.67 
Price to Sales:5.04 
EBITDA:36.41M 
Shares:334.72M 
Market Cap:3.615B 

TECHNICAL INDICATORS

MA5:9.928.9%
MA10:9.7311.0%
MA20:9.6811.5%
MA50:10.621.7%
MA100:13.3623.7%
MA200:15.1039.8%
STO9:87.80 
STO14:77.64
RSI14:59.44
WPR14:-22.36
MTM14:1.91
ROC14:0.21 
ATR:0.72 
Week High:11.001.9%
Week Low:9.5013.7%
Month High:11.355.1%
Month Low:8.8939.8%
Year High:24.85130.1%
Year Low:8.5626.2%
Volatility:91.72